The FDA has approved a new antibody-drug conjugate to treat two types of non-Hodgkin B-cell lymphomas The U.S. Food and Drug Administration (FDA) has approved polatuzumab vedotin-piiq (Polivy), in combination with a rituximab product,...
This is the first modified, donor cord blood–based stem cell therapy approved to reduce time to hematopoietic recovery and infection The U.S. Food and Drug Administration (FDA) approved omidubicel-onlv (Omisirge) for adult and pediatric...
A targeted therapy is now available for more patients with advanced bladder cancers The U.S. Food and Drug Administration (FDA) has granted accelerated approval to enfortumab vedotin-ejfv (Padcev) in combination with pembrolizumab (Keytruda) for...
The FDA has approved the monoclonal antibody retifanlimab-dlwr for some patients with Merkel cell carcinoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to retifanlimab-dlwr (Zynyz) for the treatment of adult...
A targeted therapy regimen was approved to treat some children with brain cancer The U.S. Food and Drug Administration (FDA) has approved dabrafenib (Tafinlar) in combination with trametinib (Mekinist) for pediatric patients 1 year...
The FDA approved abemaciclib with endocrine therapy for HR-positive, HER2-negative, early-stage breast cancer at high risk of recurrence. The U.S. Food and Drug Administration (FDA) has approved abemaciclib (Verzenio) with endocrine therapy (tamoxifen or...
A drug that selectively targets cancer cells was approved for the treatment of certain HR-positive breast cancers. The U.S. Food and Drug Administration (FDA) has approved sacituzumab govitecan-hziy (Trodelvy) for patients with locally advanced...
The FDA approved the immune checkpoint inhibitor dostarlimab-gxly to treat advanced uterine cancer with certain mutations. The U.S. Food and Drug Administration (FDA) has approved dostarlimab-gxly (Jemperli) for the treatment of adult patients with...
The FDA has approved the oral SERD elacestrant to treat certain patients with estrogen receptor-positive breast cancer. The U.S. Food and Drug Administration (FDA) has approved elacestrant (Orserdu) for the treatment of men and...
The FDA granted accelerated approval to the BTK inhibitor pirtobrutinib for the treatment of mantle cell lymphoma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to pirtobrutinib (Jaypirca) for the treatment...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 54,000 members worldwide drive progress against cancer.
Donate Now